大辩论:双生物标志物策略能否改善疑似急性冠脉综合征患者的分诊
本文以辩论形式讨论双生物标志物策略(和肽素联合肌钙蛋白)与单用高敏肌钙蛋白策略在疑似急性冠脉综合征分诊中的优劣。支持者认为双标志物可更早安全排除心肌梗死;2023年ESC指南推荐0h/1h或0h/2h高敏肌钙蛋白算法替代0h/3h方案。专家团队就日常实践中的争议问题进行了详细讨论。
要点
- 疑似心肌梗死是急诊入院和拥挤的常见原因,需提高分诊效率。
- 2023年ESC指南推荐0h/1h或0h/2h高敏肌钙蛋白算法替代0h/3h方案。
- 双生物标志物策略(和肽素联合肌钙蛋白)可能比现行策略更早安全排除心梗。
核心结论
- 专家团队就双生物标志物策略能否改善疑似急性冠脉综合征分诊展开辩论,讨论其利弊与争议问题。
研究设计与样本
- 本文为Great Debate辩论文章,由两个专家团队分别论述单生物标志物与双生物标志物策略的利弊。
主要发现
- 支持者认为双生物标志物策略可较现行策略更早安全排除心肌梗死。
- 当前高敏肌钙蛋白策略因需系列检测而相对较慢。
关键数值与推荐
- 2023年ESC指南推荐0h/1h或0h/2h高敏肌钙蛋白诊断算法,替代既往0h/3h方案。
- 双生物标志物策略涉及和肽素与肌钙蛋白的联合检测。
临床怎么用
- 临床需在单生物标志物与双生物标志物策略间权衡,以优化疑似急性冠脉综合征的分诊效率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Suspected myocardial infarction in patients with acute chest pain at rest is one of the most common diagnostic categories leading to emergency hospital admission and emergency department overcrowding worldwide. Efforts are being made to improve the efficiency of currently used triage and diagnostic work-up strategies. Despite major advances in recent years with the use of high-sensitivity cardiac troponin, challenges still exist regarding how to accurately and rapidly rule out or rule in myocardial infarction, as current strategies are relatively slow due to the need for serial troponin measurements. The 2023 European Society of Cardiology (ESC) guidelines recommend a 0 h/1 h or a 0 h/2 h high-sensitivity troponin diagnostic algorithm, instead of the previously suggested 0 h/3 h diagnostic protocol, to reduce the time required to discharge patients with suspected acute coronary syndrome/myocardial infarction. The ESC endorsed algorithms are not without difficulty, and alternative ways of improving triaging have been proposed, particularly a dual biomarker rule-out strategy involving the combined measurement of copeptin and troponin. Supporters of the dual biomarker strategy argue that a timely optimized algorithm can potentially allow the safe rule-out of myocardial infarction earlier than currently used strategies. In the present Great Debate article, two expert teams discuss the 'pros' and 'cons' of implementing single vs dual biomarker strategies for the rule-in and rule-out of myocardial infarction, under the moot topic 'A dual biomarker strategy improves the triage of patients with suspected acute coronary syndrome'. They address in detail many of the controversial issues currently affecting everyday clinical practice and provide insightful comments on how to best triage patients presenting with suspected acute myocardial infarction.
引用
- Giannitsis, Mueller, Huber, et al. Great debate: a dual biomarker strategy improves the triage of patients with suspected acute coronary syndrome. Eur Heart J. 2026. PMID: 42954950. doi:10.1093/eurheartj/ehag090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。